U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. Bioinformatics Tools
  4. Liver Toxicity Knowledge Base (LTKB)
  1. Bioinformatics Tools

Liver Toxicity Knowledge Base (LTKB)

LTKB is a project at the FDA's National Center for Toxicological Research to study drug-induced liver injury (DILI)

About LTKB

Liver Toxicity Knowledge Base (LTKB) is a project at the FDA’s National Center for Toxicological Research to study drug-induced liver injury (DILI). Liver toxicity is the most common cause for the discontinuation of clinical trials on a drug, as well as the most common reason for an approved drug’s withdrawal from the marketplace. Because of this, DILI has been identified by the FDA’s Critical Path Initiatives as a key area of focus in a concerted effort to broaden the agency’s knowledge for better evaluation tools and safety biomarkers.

The objective of LTKB is to develop content-rich resources to improve our basic understanding of liver toxicity and to be used by the scientific community, pharmaceutical industry, and regulatory bodies. The project involves the collection of diverse data (e.g., DILI mechanisms, drug metabolism, histopathology, therapeutic use, targets, side effects, etc.) associated with individual drugs and the use of systems biology analysis to integrate these data for DILI assessment and prediction. Importantly, both conventional and high-throughput molecular biomarker assays will be conducted for the selected drugs. The goal is to develop novel biomarkers based on knowledge accumulated from the project.

LTKB Benchmark Dataset

The LTKB benchmark dataset (LTKB-BD) was developed by NCTR scientists. LTKB-BD consists of drugs in which potential to cause DILI in humans has been established using the FDA-approved prescription drug labels.

DILIrank Dataset

The DILIrank dataset consists of 1,036 FDA-approved drugs that are divided into four classes according to their potential for causing DILI.

DILIst Dataset

The DILI severity and toxicity (DILIst) dataset consists of 1,279 drugs that are divided into two classes according to their potential for causing DILI. 


FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury.
Chen, M.J., Vijay, V., Shi, Q., Liu, Z.C., Fang, H., and Tong, W.D.
Discovery Today, 16(15-16):697-703, 2011. 

LTKB Contact Information

For questions or suggestions contact Weida Tong, Ph.D., NCTR at 870-543-7142 or weida.tong@fda.hhs.gov.

To report technical problems, contact NCTRBioinformaticsSupport@fda.hhs.gov.

Resources For You

Sign up for NCTR Bioinformatics Tools news

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top